Spravato had been cleared in the United States ... A legal loophole is allowing marijuana ads to slip past regulations and land right in front of kids on social media, a new report shows.
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...
Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.
Hosted on MSN21d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itCLICK HERE TO GO AD-FREE! Jane C Hu writes at The Microdose ... patented esketamine, which it named Spravato. The cost of the two drugs differ significantly. Per treatment session, the cost ...
Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to speak about the recent approval for Spravato as a monotherapy ...
Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.
Now, the Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray, Spravato, to be used as a standalone treatment for people with severe depression who haven't ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback